bumetanide has been researched along with Brain Inflammation in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with bumetanide did not significantly alter OX42 or GFAP intensity." | 1.46 | Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. ( Cohen, M; Glaser, N; Little, C; Lo, W; O'Donnell, M; Tancredi, D; Wulff, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glaser, N | 1 |
| Little, C | 1 |
| Lo, W | 1 |
| Cohen, M | 1 |
| Tancredi, D | 1 |
| Wulff, H | 1 |
| O'Donnell, M | 1 |
1 other study available for bumetanide and Brain Inflammation
| Article | Year |
|---|---|
Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Brain; Bumetanide; CD11b Antigen; Cere | 2017 |